GSK Tab To Clear Zantac Litigation Ledger Of 93% Of Complaints Pending In State Courts: $2.2Bn

UK pharma also reaches agreement in principle, subject to DoJ approval, to pay $70m to resolve a whistleblower complaint filed by Valisure, the testing lab which in 2019 raised concerns about a potential link between the use of drugs containing ranitidine, a histamine-2 blocker, and cancer.

• Source: Shutterstock

GSK plc’s ledger of settlements and other developments in its defense against Zantac liability complaints got its biggest addition yet on 9 October with the firm’s announcement of settling around 80,000 US state court cases for up to $2.2bn.

In an announcement, the UK pharma also said it also reached an agreement in principle, subject to final approval from the Department of Justice, to pay $70m and resolve a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe